Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 5/2007

01-05-2007 | Original Article

Modulation of soy isoflavones bioavailability and subsequent effects on bone health in ovariectomized rats: the case for equol

Authors: J. Mathey, J. Mardon, N. Fokialakis, C. Puel, S. Kati-Coulibaly, S. Mitakou, C. Bennetau-Pelissero, V. Lamothe, M. J. Davicco, P. Lebecque, M. N. Horcajada, V. Coxam

Published in: Osteoporosis International | Issue 5/2007

Login to get access

Abstract

Introduction

Soy products are of particular interest because of their potential health benefits in a range of hormonal conditions, such as osteoporosis, due to their high content in phytoestrogens. Because equol, the main metabolite from soy isoflavones, is thought to be powerful, the present study was designated to evaluate the bone-sparing effects of equol by either providing the molecule through the diet or by eliciting its endogenous production by modulating intestinal microflora by short-chain fructooligosaccharides (sc-FOS) or live microbial (Lactobacillus casei) together with daidzein, its precursor.

Methods

A comparison with daidzein and genistein was also performed. Rats (3 months old) were ovariectomised (OVX) or sham-operated (SH). Ovariectomised rats were randomly assigned to six experimental diets for 3 months: a control diet (OVX), the control diet supplemented with either genistein (G), or daidzein (D), or equol (E) at the level of 10 μg/g body weight/d. The remaining OVX rats were given daidzein at the dose of 10 μg/g body weight/d, simultaneously with short-chain FOS (Actilight®, Beghin-Meiji) (D+FOS) or Lactobacillus casei (Actimel, Danone) (D+L). The SH rats were given the same control diet as OVX.

Results

Genistein, daidzein or equol exhibited a bone sparing effect. Indeed, total femoral bone mineral density (BMD) was significantly enhanced (compared to that of OVX rats), as was the metaphyseal compartment. Bone strength was improved by E consumption, but not by genistein or daidzein given alone. As far as the FOS diet is concerned, the addition of prebiotics significantly raised efficiency of the daidzein protective effect on both femoral BMD and mechanical properties. The effects of lactobacillus were similar, except that the increase in metaphyseal-BMD was not significant.

Conclusion

In conclusion, long-term equol consumption, like genistein and daidzein, in the ovariectomized rat, provides bone sparing effects. Adding indigestible sugars, such as FOS or live microbial as L. casei, in the diet significantly improves daidzein protective effects on the skeleton.
Literature
1.
Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:1137–1141PubMedCrossRef
2.
Katz A (2003) Observations and advertising: controversies in the prescribing of hormone replacement therapy. Health Care Women Int 24:927–939PubMedCrossRef
3.
Cushman M (2003) Hormone therapies and vascular outcomes: who is at risk? J Thromb Thrombolysis 16:87–90PubMedCrossRef
4.
Welnicka-Jaskiewicz M, Jassem J (2003) The risks and benefits of hormonal replacement therapy in healthy women and in breast cancer survivors. Cancer Treat Rev 29:355–361PubMedCrossRef
5.
WHI (2002) Risks and benefits of estrogen plus progestin in healthy post menopausal women. JAMA 288:321–333CrossRef
6.
Cauley JA, Zmuda JM, Ensrud KE, Bauer DC, Ettinger B (2001) Timing of estrogen replacement therapy for optimal osteoporosis prevention. J Clin Endocrinol Metab 86:5700–5705PubMedCrossRef
7.
Setchell KD (1998) Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Am J Clin Nutr 68:1333S–1346SPubMed
8.
Murkies AL, Wilcox G, Davis SR (1998) Clinical review 92: phytoestrogens. J Clin Endocrinol Metab 83:297–303PubMedCrossRef
9.
Adlercreutz H, Mazur W (1997) Phyto-oestrogens and Western diseases. Ann Med 29:95–120PubMed
10.
Potter SM, Baum JA, Teng H, Stillman RJ, Shay NF, Erdman JW Jr (1998) Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr 68:1375S–1379SPubMed
11.
Alekel DL, Germain AS, Peterson CT, Hanson KB, Stewart JW, Toda T (2000) Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. Am J Clin Nutr 72:844–852PubMed
12.
Morabito N, Crisafulli A, Vergara C, Gaudio A, Lasco A, Frisina N, D’Anna R, Corrado F, Pizzoleo MA, Cincotta M, Altavilla D, Ientile R, Squadrito F (2002) Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study. J Bone Miner Res 17:1904–1912PubMedCrossRef
13.
Wang H-J, Murphy PA (1994b) Isoflavone content in commercial soybean foods. J Agric Food Chem 42:1666–1673CrossRef
14.
Setchell KD, Borriello SP, Hulme P, Kirk DN, Axelson M (1984) Nonsteroidal estrogens of dietary origin: possible roles in hormone-dependent disease. Am J Clin Nutr 40:569–578PubMed
15.
Day AJ, DuPont MS, Ridley S, Rhodes M, Rhodes MJ, Morgan MR, Williamson G (1998) Deglycosylation of flavonoid and isoflavonoid glycosides by human small intestine and liver beta-glucosidase activity. FEBS Lett 436:71–75PubMedCrossRef
16.
Setchell KD, Brown NM, Zimmer-Nechemias L, Brashear WT, Wolfe BE, Kirschner AS, Heubi JE (2002) Evidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability. Am J Clin Nutr 76:447–453PubMed
17.
Xu X, Harris KS, Wang HJ, Murphy PA, Hendrich S (1995) Bioavailability of soybean isoflavones depends upon gut microflora in women. J Nutr 125:2307–2315PubMed
18.
Joannou GE, Kelly GE, Reeder AY, Waring M, Nelson C (1995) A urinary profile study of dietary phytoestrogens. The identification and mode of metabolism of new isoflavonoids. J Steroid Biochem Mol Biol 54:167–184PubMedCrossRef
19.
Lampe JW, Karr SC, Hutchins AM, Slavin JL (1998) Urinary equol excretion with a soy challenge: influence of habitual diet. Proc Soc Exp Biol Med 217:335–339PubMed
20.
Setchell KD, Brown NM, Lydeking-Olsen E (2002) The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J Nutr 132:3577–3584PubMed
21.
22.
Omi N, Aoi S, Murata K, Ezawa I (1994) Evaluation of the effect of soybean milk and soybean milk peptide on bone metabolism in the rat model with ovariectomized osteoporosis. J Nutr Sci Vitaminol (Tokyo) 40:201–211
23.
Arjmandi BH, Getlinger MJ, Goyal NV, Alekel L, Hasler CM, Juma S, Drum ML, Hollis BW, Kukreja SC (1998) Role of soy protein with normal or reduced isoflavone content in reversing bone loss induced by ovarian hormone deficiency in rats. Am J Clin Nutr 68:1358S–1363SPubMed
24.
Arjmandi BH, Birnbaum R, Goyal NV, Getlinger MJ, Juma S, Alekel L, Hasler CM, Drum ML, Hollis BW, Kukreja SC (1998) Bone-sparing effect of soy protein in ovarian hormone-deficient rats is related to its isoflavone content. Am J Clin Nutr 68:1364S–1368SPubMed
25.
Anderson JJ, Garner SC (1998) Phytoestrogens and bone. Baillieres Clin Endocrinol Metab 12:543–557PubMedCrossRef
26.
Arjmandi BH, Alekel L, Hollis BW, Amin D, Stacewicz-Sapuntzakis M, Guo P, Kukreja SC (1996) Dietary soybean protein prevents bone loss in an ovariectomized rat model of osteoporosis. J Nutr 126:161–167PubMed
27.
WHI (2002) WHI (Writing group for the Women’s Health Initiative investigators). Risks and benefits of estrogen plus progestin in healthy post menopausal women. JAMA 288:321–333CrossRef
28.
Picherit C, Coxam V, Bennetau-Pelissero C, Kati-Coulibaly S, Davicco MJ, Lebecque P, Barlet JP (2000) Daidzein is more efficient than genistein in preventing ovariectomy-induced bone loss in rats. J Nutr 130:1675–1681PubMed
29.
Molis C, Flourie B, Ouarne F, Gailing MF, Lartigue S, Guibert A, Bornet F, Galmiche JP (1996) Digestion, excretion, and energy value of fructooligosaccharides in healthy humans. Am J Clin Nutr 64:324–328PubMed
30.
Ohta A, Uehara M, Sakai K, Takasaki M, Adlercreutz H, Morohashi T, Ishimi Y (2002) A combination of dietary fructooligosaccharides and isoflavone conjugates increases femoral bone mineral density and equol production in ovariectomized mice. J Nutr 132:2048–2054PubMed
31.
Mathey J, Puel C, Kati-Coulibaly S, Bennetau-Pelissero C, Davicco MJ, Lebecque P, Horcajada MN, Coxam V (2004) Fructooligosaccharides maximize bone-sparing effects of soy isoflavone-enriched diet in the ovariectomized rat. Calcif Tissue Int 28:28
32.
Robins SP (1994) Biochemical markers for assessing skeletal growth. Eur J Clin Nutr 48:S199–S209PubMed
33.
Garnero P, Delmas PD (1999) Biochemical markers of bone turnover: clinical usefulness in osteoporosis. Ann Biol Clin (Paris) 57:137–148
34.
Bennetau-Pelissero C, Le Houerou C, Lamothe V, Le Menn F, Babin P, Bennetau B (2000) Synthesis of haptens and conjugates for ELISAs of phytoestrogens. Development of the immunological tests. J Agric Food Chem 48:305–311PubMedCrossRef
35.
Pastoureau P, Chomel A, Bonnet J (1995) Specific evaluation of localized bone mass and bone loss in the rat using dual-energy X-ray absorptiometry subregional analysis. Osteoporos Int 5:143–149PubMedCrossRef
36.
Rose N, Constantin P, Leterrier C (1996) Sex differences in bone growth of broiler chickens. Growth Dev Aging 60:49–59PubMed
37.
Cook JGH (1975) Factors influencing the assay of creatinine. Ann Clin Biochem 12:219–232PubMed
38.
39.
Stepan JJ, Pospichal J, Presl J, Pacovsky V (1987) Bone loss and biochemical indices of bone remodeling in surgically induced postmenopausal women. Bone 8:279–284PubMedCrossRef
40.
Picherit C, Chanteranne B, Bennetau-Pelissero C, Davicco MJ, Lebecque P, Barlet JP, Coxam V (2001) Dose-dependent bone-sparing effects of dietary isoflavones in the ovariectomised rat. Br J Nutr 85:307–316PubMed
41.
Xu X, Wang HJ, Murphy PA, Cook L, Hendrich S (1994) Daidzein is a more bioavailable soymilk isoflavone than is genistein in adult women. J Nutr 124:825–832PubMed
42.
King RA (1998) Daidzein conjugates are more bioavailable than genistein conjugates in rats. Am J Clin Nutr 68:1496S–1499SPubMed
43.
Axelson M, Setchell KD (1981) The excretion of lignans in rats-evidence for an intestinal bacterial source for this new group of compounds. FEBS Lett 123:337–342PubMedCrossRef
44.
Uehara M, Ohta A, Sakai K, Suzuki K, Watanabe S, Adlercreutz H (2001) Dietary fructooligosaccharides modify intestinal bioavailability of a single dose of genistein and daidzein and affect their urinary excretion and kinetics in blood of rats. J Nutr 131:787–795PubMed
45.
Raffi F, Davis C, Park M, Heinze TM, Beger RD (2003) Variations in metabolism of the soy isoflavonoid daidzein by human intestinal microfloras from different individuals. Arch Microbiol 180:11–16CrossRef
46.
Miller SC, Bowman BM, Miller MA, Bagi CM (1991) Calcium absorption and osseous organ-, tissue-, and envelope-specific changes following ovariectomy in rats. Bone 12:439–446PubMedCrossRef
47.
Uebelhart D, Schlemmer A, Johansen JS, Gineyts E, Christiansen C, Delmas PD (1991) Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J Clin Endocrinol Metab 72:367–373PubMedCrossRef
48.
Ishida H, Uesugi T, Hirai K, Toda T, Nukaya H, Yokotsuka K, Tsuji K (1998) Preventive effects of the plant isoflavones, daidzin and genistin, on bone loss in ovariectomized rats fed a calcium-deficient diet. Biol Pharm Bull 21:62–66PubMed
49.
Setchell KD, Brown NM, Desai P, Zimmer-Nechemias L, Wolfe BE, Brashear WT, Kirschner AS, Cassidy A, Heubi JE (2001) Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr 131:1362S–1375SPubMed
50.
Brown NM, Setchell KD (2001) Animal models impacted by phytoestrogens in commercial chow: implications for pathways influenced by hormones. Lab Invest 81:735–747PubMedCrossRef
51.
Ohta A, Motohashi Y, Ohtsuki M, Hirayama M, Adachi T, Sakuma K (1998) Dietary fructooligosaccharides change the concentration of calbindin-D9k differently in the mucosa of the small and large intestine of rats. J Nutr 128:934–939PubMed
52.
Takahara S, Morohashi T, Sano T, Ohta A, Yamada S, Sasa R (2000) Fructooligosaccharide consumption enhances femoral bone volume and mineral concentrations in rats. J Nutr 130:1792–1795PubMed
53.
Scholz-Ahrens KE, Schaafsma G, van den Heuvel EG, Schrezenmeir J (2001) Effects of prebiotics on mineral metabolism. Am J Clin Nutr 73:459S–464SPubMed
Metadata
Title
Modulation of soy isoflavones bioavailability and subsequent effects on bone health in ovariectomized rats: the case for equol
Authors
J. Mathey
J. Mardon
N. Fokialakis
C. Puel
S. Kati-Coulibaly
S. Mitakou
C. Bennetau-Pelissero
V. Lamothe
M. J. Davicco
P. Lebecque
M. N. Horcajada
V. Coxam
Publication date
01-05-2007
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 5/2007
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-007-0351-y

Other articles of this Issue 5/2007

Osteoporosis International 5/2007 Go to the issue

Original Article

The clinical utility of measured kyphosis as a predictor of the presence of vertebral deformities

Original Article

Alcohol consumption, bone density, and hip fracture among older adults: the cardiovascular health study

Short Communication

The association between non-melanoma skin cancer and osteoporotic fractures—a population-based record linkage study

Letter

Cost effectiveness of screening strategies using BMD measurements for hip fracture prevention in elderly women

Erratum

Comparative study of axial and femoral bone mineral density and parameters of mandibular bone quality in patients receiving dental implants

Short Communication

Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases